[Form 4] GLOBUS MEDICAL INC Insider Trading Activity

Rhea-AI Filing Summary

Director Ann D. Rhoads reported the sale of 10,000 shares of Class A Common Stock of Globus Medical, Inc. (GMED) on 09/15/2025 under a pre-established Rule 10b5-1 trading plan dated November 8, 2024. The weighted-average sale price was $58.46, with individual trade prices ranging from $58.22 to $58.81. After the reported dispositions, the reporting person beneficially owned 25,384 shares, held directly. The Form 4 was executed by an attorney-in-fact on behalf of the reporting person.

Positive

• Transaction executed under a Rule 10b5-1 plan, indicating the sale was prearranged and not an ad-hoc insider transaction.
• Complete disclosure of price range and weighted-average price ($58.22 - $58.81; weighted-average $58.46) with offer to provide per-trade details on request.

Negative

• Director reduced direct holdings by selling 10,000 shares, lowering beneficial ownership to 25,384 shares.
• Sale represents insider liquidity, which some investors may interpret negatively despite being under a 10b5-1 plan.

Insights

Securities Analyst

TL;DR: A director executed a planned sale of 10,000 GMED shares via a 10b5-1 plan; ownership was reduced but remains disclosed and routine.

The transaction was effected under a documented Rule 10b5-1 trading plan, which generally indicates the sale was prearranged and not based on material nonpublic information contemporaneously. The filing discloses a weighted-average price of $58.46 and a post-transaction direct beneficial ownership of 25,384 shares. For investors, this is a straightforward insider liquidity event rather than a governance or operational change. No derivatives or additional conditions are reported.

Corporate Governance Expert

TL;DR: Director sale appears compliant and pre-planned; disclosure is complete with price range and 10b5-1 plan citation.

The Form 4 clearly identifies the filer as a director and specifies the November 8, 2024 10b5-1 plan as the mechanism for the sale, which supports procedural compliance. The filer provided the weighted-average price and disclosed willingness to supply transaction-level price details on request. The form shows direct ownership only and contains an attorney-in-fact signature, consistent with standard practice for timely reporting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RHOADS ANN D

(Last) (First) (Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVENUE

(Street)

AUDUBON PA 19403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/15/2025		S(1)		10,000	D	$58.46(2)	25,384	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was effected pursuant to a Rule 10b5-1 trading plan dated November 8, 2024 executed by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at a price range of $58.22-$58.81, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.

	/s/ Kelly G. Huller, Attorney-in-Fact	09/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Ann D. Rhoads report on Form 4 for GMED?

The filer reported the sale of 10,000 Class A shares on 09/15/2025, executed under a 10b5-1 trading plan with a weighted-average price of $58.46.

How many GMED shares does the reporting person own after the sale?

After the reported transactions, the reporting person beneficially owns 25,384 shares, held directly.

Was the sale a single trade or multiple trades?

The filing states the sale was executed in multiple transactions at prices ranging from $58.22 to $58.81; the weighted-average price reported is $58.46.

What authority signed the Form 4 for the reporting person?

The Form 4 was signed by Kelly G. Huller, Attorney-in-Fact on 09/16/2025 on behalf of the reporting person.

Was the sale part of a Rule 10b5-1 plan?

Yes. The filing explicitly states the sale was effected pursuant to a Rule 10b5-1 trading plan dated November 8, 2024.